Hypertension induced by chemotherapeutic and immunosuppresive agents: a new challenge.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Critical reviews in oncology/hematology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2014.08.004PMID 25217090
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug induced hypertension--An unappreciated cause of secondary hypertension.

  2015cited by this paper
• Cardiotoxicity Associated with the Tyrosine Kinase Inhibitor Sunitinib

  2013influential reference
• Drug-induced hypertension: an unappreciated cause of secondary hypertension.

  2012cited by this paper
• Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

  2011cited by this paper
• Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant

  2011cited by this paper
• Bevacizumab-Induced Hypertension

  2011cited by this paper
• An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition.

  2011cited by this paper
• Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension.

  2011cited by this paper
• Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

  2010cited by this paper
• Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?

  2010cited by this paper
• Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors

  2009cited by this paper
• Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease.

  2009cited by this paper
• Etiology and pathogenesis of systemic hypertension

  2009cited by this paper
• Management of hypertension in angiogenesis inhibitor-treated patients.

  2009cited by this paper
• Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression

  2009cited by this paper
• [Nephrotoxicity of tacrolimus and preventive effect of diltiazem: experiment with rats].

  2009cited by this paper
• Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation.

  2008cited by this paper
• Heart failure associated with sunitinib malate

  2008cited by this paper
• Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer

  2008cited by this paper
• Vascular complications of selected cancer therapies

  2008cited by this paper
• Secondary Hypertension: Interfering Substances

  2008cited by this paper
• Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.

  2008cited by this paper
• Cortisol and cardiovascular disease

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.

  2007cited by this paper
• Chemotherapy agents and hypertension: A focus on angiogenesis blockade

  2007cited by this paper
• Renal and vascular hypertension-induced inflammation: role of angiotensin II

  2006cited by this paper
• An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients

  2005cited by this paper
• EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.

  2004cited by this paper
• Prognostic importance of comorbidity in a hospital-based cancer registry.

  2004cited by this paper
• Erythropoietin‐Induced Hypertensive Urgency in a Patient with Chronic Renal Insufficiency: Case Report and Review of the Literature

  2003cited by this paper
• Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice.

  2003cited by this paper
• Dexamethasone induction of hypertension and diabetes is PPAR-α dependent in LDL receptor–null mice

  2003cited by this paper
• The cardiovascular effects of erythropoietin.

  2003cited by this paper
• Pathogenesis of Hypertension

  2003cited by this paper
• Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

  2002cited by this paper
• Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation.

  2001cited by this paper
• Insights Into Glucocorticoid-Associated Hypertension.

  2001cited by this paper
• The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA.

  2001cited by this paper
• Cyclosporin-induced hypertension.

  2001cited by this paper
• Cardiovascular morbidity in long-term survivors of metastatic testicular cancer.

  2000cited by this paper
• Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney.

  2000cited by this paper
• Erythropoietin and arterial hypertension.

  2000cited by this paper
• Cushing, cortisol, and cardiovascular disease.

  2000cited by this paper
• Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients.

  2000cited by this paper
• Mechanism of erythropoietin-induced hypertension.

  1999cited by this paper
• What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.

  1999cited by this paper
• Aldosterone, salt and cardiac fibrosis.

  1997cited by this paper
• Effect of antihypertensives on plasma potassium in end stage renal disease: a retrospective study.

  1997cited by this paper
• Isradipine for the prevention of cyclosporine-induced hypertension in allogeneic bone marrow transplant recipients: a randomized, double-blind study.

  1997cited by this paper
• Glucocorticoids and hypertension in man.

  1997cited by this paper
• A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results.

  1996cited by this paper
• Do Non-Potassium-Sparing Diuretics Increase the Risk of Sudden Cardiac Death in Hypertensive Patients?

  1994cited by this paper
• Hypertension after renal transplantation.

  1993cited by this paper
• Anaphylactoid reactions, angiotensin-converting enzyme inhibitors and extracorporeal hemotherapy.

  1993cited by this paper
• Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants.

  1993cited by this paper
• Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients.

  1993cited by this paper
• Renal Function and Blood Pressure in Patients Receiving Long-Term, Low-Dose Cyclosporine Therapy for Idiopathic Autoimmune Uveitis

  1992cited by this paper
• Adrenocorticotrophin and steroid-induced hypertension in humans.

  1992cited by this paper
• Complications Associated with Immunosuppressive Therapy and Their Management

  1991cited by this paper
• Acute coronary events following cisplatin-based chemotherapy.

  1990cited by this paper
• The effects of FK 506 on renal function after liver transplantation.

  1990cited by this paper
• Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation.

  1989cited by this paper
• Reversible renal failure due to the use of captopril in a renal allograft recipient treated with cyclosporin.

  1989cited by this paper
• Cyclosporine--mechanism of action.

  1988cited by this paper
• Cyclosporine--mechanism of action.

  1988cited by this paper
• The incidence of gout in renal transplant recipients.

  1987cited by this paper
• Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis.

  1986cited by this paper
• Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft‐versus‐host disease prophylaxis

  1985cited by this paper

• Comorbidity of hypertension and lung cancer: interplay of genetics and environment

  2025cites this paper
• Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors.

  2025cites this paper
• Association between triglyceride-glucose index and hypertension in adults with cancer from NHANES 2005–2018: a cross-sectional study

  2025cites this paper
• Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials.

  2024cites this paper
• Higher Mortality in Patients With Diffuse Large B-cell Lymphoma Pre-Existing Arterial Hypertension-Real World Data of the Polish Lymphoma Research Group.

  2024cites this paper
• Arterial hypertension and anticancer drug therapy: pathophysiological relationships and clinical significance

  2023cites this paper
• Cardiovascular Disease as a Consequence or a Cause of Cancer: Potential Role of Extracellular Vesicles

  2023cites this paper
• The use of renin angiotensin aldosterone system inhibitors may be associated with decreased mortality after cancer surgery

  2022cites this paper
• Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs

  2021cites this paper
• Impact of a Pharmacist-Led Hypertension Management Program for Oral Chemotherapy in a Specialty Pharmacy Setting

  2021cites this paper
• Calcium-channel-blockers exhibit divergent regulation of cancer extravasation through the mechanical properties of cancer cells and underlying vascular endothelial cells

  2021cites this paper
• Unravelling the tangled web of hypertension and cancer.

  2021cites this paper
• Risk Stratification and Management of Arterial Hypertension and Cardiovascular Adverse Events Related to Cancer Treatments: An Oncology Network from Piedmont and Aosta Valley (North-Western Italy) Consensus Document

  2021cites this paper
• Onco-hypertension: Overview of hypertension with anti-cancer agents

  2021cites this paper
• The core components of cardio-oncology rehabilitation.

  2021cites this paper
• Opportunities for improved cardiovascular disease prevention in oncology patients.

  2020cites this paper
• Arterial hypertension in adults. Clinical guidelines 2020

  2020cites this paper
• Intriguing relationship between antihypertensive therapy and cancer

  2019cites this paper
• Arterial hypertension in patients under antineoplastic therapy: a systematic review

  2019cites this paper
• Guía ESC/ESH 2018 sobre el diagnóstico y tratamiento de la hipertensión arterial

  2019cites this paper
• Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association.

  2019cites this paper
• Drug-Induced and Exogenous Hypertension

  2019cites this paper
• Factors Affecting the Morbidity and Mortality of Malignancy Patients Admitted to the Emergency Department

  2019cites this paper
• Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury

  2019cites this paper
• Co-administration of Shexiang Baoxin Pill and Chemotherapy Drugs Potentiated Cancer Therapy by Vascular-Promoting Strategy

  2019cites this paper
• VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive Processes

  2018cites this paper
• 2018 ESC/ESH Guidelines for the management of arterial hypertension.

  2018cites this paper
• The Role of Angiogenesis Inhibitors in Hypertension: Following “Ariadne’s Thread”

  2018cites this paper
• Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies – part 1

  2018cites this paper
• Echocardiographic reference ranges for normal non-invasive myocardial work indices: results from the EACVI NORRE study.

  2018cites this paper
• Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2.

  2017cites this paper
• Hypertension and Cancer

  2017cites this paper
• Chapter 10 – Cardiovascular Complications from Cancer Therapy: Hypertension–Focus on Vascular Endothelial Growth Factor Inhibitors

  2016cites this paper
• Vascular Complications of Cancer Chemotherapy

  2016cites this paper
• Hypertension in Oncology and Stem-Cell Transplant Patients

  2016cites this paper
• Cardiotoxic Agents in Oncology: What Is of Importance?

  2016cites this paper
• Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats

  2016cites this paper
• The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease

  2015cites this paper
• Hypertension and renal disease during anti-cancer therapies

  year unknowncites this paper